Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–
3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate …

For the past 30 years, improvements in the survival of patients with osteosarcoma have been
mostly incremental. Despite evidence of genomic instability and a high frequency of …

Effective antitumor therapeutics with distinctive bactericidal and osteogenic properties are in
high demand for comprehensive osteosarcoma treatment. Here, a “scaffold engineering” …

Osteosarcoma patient survival has remained stagnant for 30 years. Novel therapeutic
approaches are needed to improve outcomes. We examined the expression of Programmed …

Progressively increasing failure rates, high cost, poor bioavailability, poor safety, limited
efficacy, and a lengthy design and testing process associated with cancer drug development …

Osteosarcoma (OS) is a highly aggressive pediatric cancer, characterized by frequent lung
metastasis and pathologic bone destruction. Vascular endothelial growth factor A (VEGFA) …

Highlights•Although rare, bone cancers frequently cause death in the pediatric population.•
Osteosarcoma patient survival has plateaued over the last 20 years.•The large tumor …

Osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma are the most common malignant
musculoskeletal tumors in children and adolescents. Today, most patients can be cured …

Bones provide essential functions and are sites of unique biochemistry and specialized
cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has …

Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients
who present with localized osteosarcoma can be expected to be cured of their disease with …